PLB-1001 CAS 1440964-89-5

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

1440964-89-5

Name

PLB-1001

Syn­onyms

1,2,4-Triazolo[4,3-b]pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-[difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl]- [ACD/​Index Name]
6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-[difluor(6-fluor-2-methyl-2H-indazol-5-yl)methyl][1,2,4]triazolo[4,3-b]pyridazin [Ger­man] [ACD/IUPAC Name]
6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-[difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl][1,2,4]triazolo[4,3-b]pyridazine [ACD/IUPAC Name]
6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-[difluoro(6-fluoro-2-méthyl-2H-indazol-5-yl)méthyl][1,2,4]triazolo[4,3-b]pyridazine [French] [ACD/IUPAC Name]
1440964-89-5 [RN]
6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine
Boz­i­tinib
Boz­i­tinib (PLB-1001)

SMILES

CN1C=C2C=C(C(F)=CC2=N1)C(F)(F)C1=NN=C2C=CC(=NN21)C1=CN(N=C1)C1CC1

Std­InChI

InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3

Std­InChIKey

QHXLXUIZUCJRKV-UHF­F­­FAOYSA-N

Mol­e­c­u­lar Formula

C₂₀H₁₅F₃N₈

Mol­e­c­u­lar Weight

424.382

Prop­er­ties

Struc­ture

Safe­ty Data

Sym­bol

Sig­nal Word

Warn­ing

WGK Germany

3

MSDS Download

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our 

Water

Loss on Drying

Residue on Ignition

Sin­gle Impurity

Total Impu­ri­ties

Shelf Life

2 years

Stor­age

Store at -20°C and away from light

Known Appli­ca­tionc

Boz­i­tinib is a recep­tor tyro­sine kinase inhibitor tar­get­ing the cell-mes­enchy­­mal-epithe­lial tran­si­tion fac­tor (c-MET), capa­ble of inhibit­ing the pro­lif­er­a­tion of tumor cells with ele­vat­ed c-MET expres­sion. This drug can pen­e­trate the blood-brain bar­ri­er and has been reg­is­tered for 8 clin­i­cal tri­als domes­ti­cal­ly, with indi­ca­tions includ­ing non-small cell lung can­cer (NSCLC), gliomas, and more.

Gen­er­al View of Documents

Links

This prod­uct is devel­oped by our R&D com­pa­ny Cam­ing Phar­ma­ceu­ti­cal Lim­it­ed (http://​www​.cam​ing​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.